A Randomized, Single-blind, Placebo-controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects With Chronic Kidney Disease Not Requiring Dialysis

Trial Profile

A Randomized, Single-blind, Placebo-controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects With Chronic Kidney Disease Not Requiring Dialysis

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2015

At a glance

  • Drugs Roxadustat (Primary)
  • Indications Anaemia
  • Focus Adverse reactions
  • Sponsors FibroGen
  • Most Recent Events

    • 12 Aug 2015 Results were published in a FibroGen media release.
    • 03 Aug 2015 Results published in the Nephrology Dialysis Transplantation.
    • 18 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top